Skip Navigation

Cardiovascular Research 1995 30(2):291-298; doi:10.1016/S0008-6363(95)00050-X
© 1995 by European Society of Cardiology
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sigusch, H. H.
Right arrow Articles by Weber, K. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sigusch, H. H.
Right arrow Articles by Weber, K. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1995, European Society of Cardiology

Angiotensin-II-induced increase in transcoronary protein clearance: role of hypertension vs. nitric oxide or cyclo-oxygenase products

Holger H. Siguscha, Ruchong Oua, Laxmansa C. Katwaa, Scott E. Campbella, Venkataseshu K. Ganjamb, Hanumanth K. Reddya and Karl T. Weber*,a

aDivision of Cardiology, Department of Internal Medicine and Dalton Cardiovascular Research Center, University of Missouri Health Sciences Center, Columbia, MO, USA
bCollege of Veterinary Medicine, Columbia, MO, USA

* Corresponding author: University of Missouri Health Sciences Center, Division of Cardiology, Room MA 432 Medical Sciences Building, Columbia, MO 65212, USA. Tel. (+314) 882-8580; Fax (+314) 884-4691.

Elevations in plasma angiotensin II (AngII) are associated with an efflux of plasma macromolecules into the perivascular and contiguous interstitial space. Whether this exudative response is related to associated hypertension or another effect of AngII is uncertain. We therefore monitored plasma and cardiac lymph total protein, albumin and fibronectin and calculated transvascular clearances for total protein (TVPC) and albumin (TVAC) and lymph fibronectin transport (LFT) every 30 min in open-chested, instrumented dogs. After baseline observations were obtained over 30 min, pressor (250 ng · kg · min–1) or nonpressor (11 ng · kg · min–1) doses of AngII were given intravenously for 90 min. Saline-treated, instrumented dogs served as controls. To address a potential secondary effect of AngII on vascular protein clearance, we monitored lymph prostaglandin E2 and cGMP (a marker of released nitric oxide, NO). At ≥ 30 min, each dose of AngII was associated with a significant (P ≤ 0.05) and comparable increase in TVPC, TVAC and LFT over baseline, indicating that increase in protein clearance was not related to elevated arterial pressure. Lymph cGMP rose significantly (P ≤ 0.05) at 30 min for each dose of AngII and remained elevated thereafter. Lymph PGE2 was increased at ≥ 60 min (P ≤ 0.05) but only with the pressor dose. To determine the contribution of NO and PGE2 on AngII-induced transcoronary protein clearance, each dose of AngII was accompanied by co-administration of either the NO synthase inhibitor, NG-nitro-L-arginine methyl ester (L-NAME), or the cyclo-oxygenase inhibitor, indomethacin. L-NAME completely inhibited the release of cGMP and the increase in protein clearance was not seen. Indomethacin suppressed the release of PGE2, but did not prevent the increase in protein clearance. Thus, AngII-induced increase in transcoronary protein clearance is not related to arterial hypertension or the release of PGE2, but instead appears to be mediated by NO release.

KEYWORDS Angiotensin II; Nitric oxide; L-NAME; Prostaglandin; Hypertension; Dog, anesthetized


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
Y. Sun, F. J.A Ramires, and K. T Weber
Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion
Cardiovasc Res, July 1, 1997; 35(1): 138 - 147.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.